| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/13/2001 | USRE37053 Particles incorporating surfactants for pulmonary drug delivery |
| 02/13/2001 | US6187938 Transdermal penetration enhancers |
| 02/13/2001 | US6187907 Conjugate of three crosslinked polypeptide chains containing tripeptide or hexapeptide repeat sequences aligned to form triple helix coil and ligand covalently attatched to template; modeling; drug screening |
| 02/13/2001 | US6187842 Sugar compounds, gelling agents, gelling agent compositions processes for the preparation of them, and gel compositions |
| 02/13/2001 | US6187818 Prostaglandins formulation and process |
| 02/13/2001 | US6187803 Treating allergic disease, autoimmune disease, immunodeficiency syndrome, inflammatory disease or eosinophilia by orally administering a histamine-added immunoglobulin and carrier; tablets, capsules |
| 02/13/2001 | US6187765 Mometasone furoate suspensions for nebulization |
| 02/13/2001 | US6187763 Containing petrolatum solid oil, squalane liquid oil, ionic polysaccharide and nonionic surfactant |
| 02/13/2001 | US6187748 Treatment and prevention of hiv |
| 02/13/2001 | US6187747 Hydrophilic carrier medium comprising propylene glycol, esters of propylene glycol and polyoxyethylene hydrogenated castor oils |
| 02/13/2001 | US6187742 Method for healing and repair of connective tissue attachment |
| 02/13/2001 | US6187593 Methods for treating a fibrin encapsulated tumor using a fibrin specific monoclonal antibody and compositions used therein |
| 02/13/2001 | US6187536 In vitro diagnosis of tumors in humans; analyzing preferential organ tissue for presence of cholecystokinin messenger ribonucleic acids, presence of cholecystokinin messenger ribonucleic acids indicates human has a tumor |
| 02/13/2001 | US6187347 Coagulation of blood from wounds |
| 02/13/2001 | US6187346 Intrauterine chemical cauterizing method and composition |
| 02/13/2001 | US6187345 Flutamide compositions and preparations |
| 02/13/2001 | US6187344 Powdered pharmaceutical formulations having improved dispersibility |
| 02/13/2001 | US6187342 Solid medicaments obtained by extrusion of an isomalt-containing polymer-active substance melt |
| 02/13/2001 | US6187341 Trovafloxacin mesylate tablet |
| 02/13/2001 | US6187339 Solid pharmaceutical composition comprising an excipient capable of binding water |
| 02/13/2001 | US6187330 Local delivery of angiogenic amounts of basic fibroblast growth factor or vascular endothelial growth factor. |
| 02/13/2001 | US6187327 Contains 2,4,4'-trichloro-2'-hydroxydiphenyl ether as the antimicrobial agent |
| 02/13/2001 | US6187290 Foamable carrier and an active ingredient; especially useful for medical applications, for example in treating burns. |
| 02/13/2001 | US6187288 Stable microbubble suspensions as enhancement agents for ultrasonic echography |
| 02/13/2001 | US6187287 Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
| 02/13/2001 | CA2280316A1 Transdermal, oral and intravenous formulations of 2,3-dimethoxy-5-methyl-6-dacaprenyl-1,4-benzoquinone |
| 02/13/2001 | CA2192674C Methods for treating respiratory disease |
| 02/13/2001 | CA2190753C Anti-acne compositions |
| 02/13/2001 | CA2147806C Polyenic compounds; pharmaceutical and cosmetic compositions containing them and uses |
| 02/13/2001 | CA2146637C Pharmaceutical compositions and methods for treating cold symptoms |
| 02/13/2001 | CA2139358C Human growth hormone aqueous formulation |
| 02/13/2001 | CA2067224C Hirudin/polyalkylene glycol conjugates |
| 02/13/2001 | CA2059288C Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties |
| 02/13/2001 | CA2021501C Topical pharmaceutical compositions |
| 02/13/2001 | CA2016505C Water soluble high molecular polymerized drug preparation |
| 02/09/2001 | CA2315594A1 Process for the preparation of aqueous formulations for ophthalmic use |
| 02/08/2001 | WO2001009390A1 Tenascin-c nucleic acid ligands |
| 02/08/2001 | WO2001009342A1 Microencapsulated nitric oxide synthase source |
| 02/08/2001 | WO2001009297A1 A method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/08/2001 | WO2001009198A1 Temperature sensitive polymers |
| 02/08/2001 | WO2001009195A1 Cyclodextrins monosubstituted to persubstituted by fluoroalkyl groups, preparation and use thereof |
| 02/08/2001 | WO2001009188A1 Binding moieties for fibrin |
| 02/08/2001 | WO2001009165A2 ACTIVATION OF PEPTIDE PRODRUGS BY hK2 |
| 02/08/2001 | WO2001009156A1 HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
| 02/08/2001 | WO2001009151A1 Process for preparing a charcoal-gm1 complex |
| 02/08/2001 | WO2001009000A1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 02/08/2001 | WO2001008714A1 Cartilage or bone matrix as a nucleic acid delivery vehicle |
| 02/08/2001 | WO2001008708A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 02/08/2001 | WO2001008707A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 02/08/2001 | WO2001008706A1 Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| 02/08/2001 | WO2001008704A2 Dendrimer-photosensitizer complexes for medical applications |
| 02/08/2001 | WO2001008687A1 Beta-carboline pharmaceutical compositions |
| 02/08/2001 | WO2001008686A1 Beta-carboline pharmaceutical compositions |
| 02/08/2001 | WO2001008680A1 Preparations for reducing oxygen consumption during physical efforts |
| 02/08/2001 | WO2001008674A1 Sulfonamide derivatives and remedies for allodynia |
| 02/08/2001 | WO2001008671A2 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 02/08/2001 | WO2001008662A1 Liquid pharmaceutical composition based on paracetamol |
| 02/08/2001 | WO2001008661A2 Opioid sustained-released formulation |
| 02/08/2001 | WO2001008659A1 Pharmaceutical compositions for topical application to treat erectile dysfunction |
| 02/08/2001 | WO2001008636A2 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| 02/08/2001 | WO2001008632A2 Colloidal composition for esthetic correction |
| 02/08/2001 | WO2001008505A2 Methods for suppressing appetite and enhancing exercise and recovery |
| 02/08/2001 | WO2001008496A1 Antiparasitic formulation |
| 02/08/2001 | WO2001008495A1 Rotavirus vaccine formulations |
| 02/08/2001 | WO2000069894A3 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 02/08/2001 | WO2000067798A3 Enhanced delivery of nucleic acid-based drugs |
| 02/08/2001 | WO2000066528A3 Quinones for treatment of diseases |
| 02/08/2001 | WO2000066206A3 Compositions for aerosolization and inhalation |
| 02/08/2001 | WO2000066141A3 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 02/08/2001 | WO2000065024A3 Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
| 02/08/2001 | WO2000064485A8 Specifically targeted catalytic antagonists and uses thereof |
| 02/08/2001 | WO2000061183A3 Verotoxin treatment of lymphomas |
| 02/08/2001 | WO2000059851A8 Derivatives of venlafaxine and methods of preparing and using the same |
| 02/08/2001 | WO2000057919A3 Lipid-based artificial particles inducing cell-mediated immunity |
| 02/08/2001 | WO2000007627A8 Topical delivery systems for active agents |
| 02/08/2001 | DE19937219A1 Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie A process for the purification of the blood clotting factor VII-activating protease, its pro-enzyme or a mixture of both proteins by ion-exchange chromatography |
| 02/08/2001 | DE19937218A1 Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie A process for the purification of the blood clotting factor VII-activating protease, its pro-enzyme or a mixture of both proteins by affinity chromatography |
| 02/08/2001 | DE19937116A1 Moxifloxacin Kochsalzformulierung Moxifloxacin saline formulation |
| 02/08/2001 | DE19937115A1 Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon An aqueous pharmaceutical formulation of moxifloxacin or salts thereof |
| 02/08/2001 | DE19936545A1 Nasal pharmaceutical composition, useful e.g. for delivering corticosteroids, comprises at least one water-soluble active ingredient and a neutral oil e.g. a medium-chain fatty acid triglyceride or propylene glycol ester |
| 02/08/2001 | DE19936543A1 Composition for intranasal administration of water-insoluble drugs, e.g. scopolamine, budesonide or diazepam, comprising a solution of the water-insoluble or sparingly water-soluble drug in a neutral oil e.g. a triglyceride |
| 02/08/2001 | DE19935302A1 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen Conjugates and methods for their preparation and their use for transporting molecules across biological membranes |
| 02/08/2001 | DE10037121A1 Antipyretic composition for treating intensively reared animals, comprising stable, concentrated paracetamol solution in polyethylene glycol and/or polypropylene glycol, added to drinking water or sprayed on feed |
| 02/08/2001 | CA2393452A1 Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| 02/08/2001 | CA2391348A1 Enhanced delivery via serpin enzyme complex receptor |
| 02/08/2001 | CA2380837A1 High affinity tgf.beta. nucleic acid ligands and inhibitors |
| 02/08/2001 | CA2380787A1 Microencapsulated nitric oxide synthase source |
| 02/08/2001 | CA2380473A1 Tenascin-c nucleic acid ligands |
| 02/08/2001 | CA2380379A1 A method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/08/2001 | CA2379987A1 Opioid sustained-released formulation |
| 02/08/2001 | CA2379703A1 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 02/08/2001 | CA2379663A1 Cartilage or bone matrix as a nucleic acid delivery vehicle |
| 02/08/2001 | CA2378864A1 Rotavirus vaccine formulations |
| 02/08/2001 | CA2378155A1 Colloidal composition for esthetic correction |
| 02/08/2001 | CA2376245A1 Binding moieties for fibrin |
| 02/07/2001 | EP1074620A1 Monomeric protein of the TGF-beta family |
| 02/07/2001 | EP1074616A1 Process for purification of the factor VII-activating protease, its proenzyme or a mixture of both proteins, by ion-exchange chromatography |
| 02/07/2001 | EP1074615A1 Methods for purification of Factor VII activating Protease, its proenzyme or a mixture of both forms, by affinity chromatography |
| 02/07/2001 | EP1074263A2 Pharmaceutical compositions of macrolides or cyclosporine with a polyethoylate saturated hydroxy-fatty acid |
| 02/07/2001 | EP1074255A1 Medicinal compositions |